Back to top

messenger-rna: Archive

Sundeep Ganoria

Should You Buy Moderna Stock Following Its Cancer Breakthrough?

MRNA's cancer therapy scores a phase III win, strengthening its mRNA platform, while pipeline risks and competition remain key concerns.

MRNAPositive Net Change PFEPositive Net Change MRKNegative Net Change BNTXPositive Net Change